Open Nav

Please submit your session questions in advance at

Rockwell Medical,Inc

Rockwell Medical, Inc (Rockwell Medical), is a specialty pharmaceutical company targeting anemia management in end-stage renal disease (ESRD), chronic kidney disease (CKD) and other anemia related disease areas. Triferic is the ONLY FDA APPROVED product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. In addition, Rockwell is an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates / dialysates (used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream, to dialysis providers and distributors in the U.S. and abroad. Rockwell has two Triferic formulation:

Triferic dialysate, to be launched in the first half of 2019 and Triferic IV for first half 2019 NDA submission. Rockwell Medical owns global Triferic rights and is seeking partnership ex-USA, including Europe and Japan. We have an established China partner with anticipated 2019 China NDA.

  • Date:Monday, February 11
  • Time:1:15 PM - 1:30 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23488
  • Goal for Presentation:Increase Rockwell Medical & Triferic awareness with investors/analysts for 2H19 financing
  • Company
  • Company HQ City:Wixom
  • Company HQ State:Michigan
  • Company HQ Country:United States
  • Market Cap:$180 million
  • Ticker:RMTI
  • Exchange:NASDAQ
  • CEO/Top Company Official:Stuart Paul
  • Year Founded:1996
  • Main Therapeutic Focus:Other
  • Lead Product in Development:Triferic (ferric pyrophosphate citrate)
  • Development Phase of Primary Product:Phase IV
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):Two
  • Additional Information/Comments:Triferic is the ONLY FDA APPROVED therapeutic to replace iron and maintain hemoglobin in CKD dialysis patients. U.S. commercial launch is planned for 1H2019. With its Triferic IV form 2019 NDA submission (est 2020 FDA approval) and planned EMA endorsed Phase 3 European trial, Rockwell is poised for U.S. growth and global expansion with the Triferic therapeutic platform. Triferic Clinical trials are underway in China with partner Wanbang / Fosun Pharmaceutical with 2019 NDA submission / 2020 approval anticipated. Rockwell's Current partners in Latin America include Quimica Europea (Peru) and BioRenal (Chile). In addition, Rockwell Medical is the #2 supplier of "base" dialysis concentrates in the U.S. a strategic asset with potential to expand and generate cash flow to support innovation opportunities.
Stuart Paul
Rockwell Medical, Inc